Syringes with needles are seen in front of a displayed Moderna logo in this illustration taken, November 27, 2021.
Moderna said the companies would use Immatics' drug discovery platform to develop mRNA-based cancer vaccines, and also study its own cancer vaccine for use in combination with Immatics' cancer therapy IMA203.
Moderna is already developing a cancer vaccine with Merck (MRK.N), which was shown to cut the risk of recurrence or death by 44% in patients with deadly skin cancer melanoma, in a mid-stage trial.
Under the terms of collaboration, Moderna will lead the development and commercialization of the cancer vaccines resulting from the collaboration, while Immatics will be responsible for pre-clinical and potential early-stage studies.
Immatics will also receive research funding and is eligible for development, regulatory, and commercial milestone payments that could exceed $1.7 billion, Moderna said.
Persons:
Dado Ruvic, Moderna, Immatics, Christy Santhosh, Anil D'Silva, Shounak
Organizations:
REUTERS, Moderna, Merck, Thomson
Locations:
COVID, Bengaluru